The wearable cardioverter-defibrillator (WCD) was introduced to provide protection from sudden cardiac death (SCD) in patients with transiently elevated risk or during ongoing risk stratification. Benefits and clinical characteristics of routine WCD use remain to be assessed in larger patient populations. This study aims to identify determinants of WCD compliance, therapies, and inappropriate alarms in a real-life cohort. A total of 106 cases (68.9% male) were included between 11/2010 and 04/2016. WCD therapies, automatically recorded arrhythmia episodes, inappropriate WCD alarms, patient compliance, and outcome after WCD prescription were analyzed. Median duration of WCD use was 58.5 days. Average daily wearing time was 22.7 h. Compliance was reduced in patients ≤ 50 years. Three patients received WCD therapies (2.8%). In one case ventricular fibrillation (VF) was appropriately terminated with the first shock. Two patients received inappropriate WCD therapies due to WCD algorithm activation during ventricular pacemaker stimulation. One patient died of asystole while carrying a WCD (0.9%). Additional arrhythmias detected comprised self-terminating sustained ventricular tachycardia (VT; 2.8%), non-sustained VT (2.8%), and supraventricular arrhythmias (5.7%). Inappropriate WCD alarms due to over-/undersensing occurred in 77/106 patients (72.6%), of which 41 (38.7%) experienced ≥ 10 inappropriate WCD alarms during the prescription period. Thirteen patients (12.3%) displayed a mean of > 1 inappropriate alarms/day. WCD use was associated with high compliance and provided protection from VT/VF-related SCD. The majority of patients experienced inappropriate WCD alarms. Alterations in QRS morphology during pacemaker stimulation require consideration in WCD programming to prevent inappropriate alarms.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00380-018-1181-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
False Alarms in Wearable Cardioverter Defibrillators-A Relevant Issue or an Insignificant Observation.
J Clin Med
December 2024
Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charité (DHZC), Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany.
The wearable cardioverter defibrillator (WCD) has emerged as a valuable tool used for temporary protection from sudden cardiac death. However, since the WCD uses surface electrodes to detect arrhythmias, it is susceptible to inappropriate detection. Although shock conversion rates for the WCD are reported to be high for detected events, its efficacy in clinical practice tends to be degraded by patient noncompliance.
View Article and Find Full Text PDFAppropriate use of wearable defibrillators with multiparametric evaluation to avoid unnecessary defibrillator implantation.
Open Heart
September 2024
Clinical and Rehabilitation Cardiology Division, San Filippo Neri Hospital, Rome, Italy.
Article Synopsis
- Wearable cardioverter-defibrillators (WCD) are non-invasive devices designed for patients at risk of life-threatening arrhythmias, providing continuous monitoring and the ability to deliver prompt defibrillation when necessary.
- The study involved 41 patients monitored from November 2022 to May 2024, focusing on tailored therapy through regular check-ups and remote monitoring, with a significant portion of patients experiencing conditions like hypertension and heart failure.
- Results showed that the majority of patients did not require further device interventions; only 29% ultimately needed an implantable cardioverter-defibrillator (ICD), suggesting that WCD use can help optimize treatment decisions and reduce unnecessary ICD implants.
A Patch Wearable Cardioverter-Defibrillator for Patients at Risk of Sudden Cardiac Arrest.
J Am Coll Cardiol
August 2024
Baylor Scott and White Research Institute, Dallas, Texas, USA; Department of Medicine, University of Mississippi, Jackson, Mississippi, USA. Electronic address:
Background: For many patients, sudden cardiac arrest (SCA) risk is elevated temporarily. Wearable cardioverter-defibrillators (WCDs) can monitor and treat SCA during these temporary periods. Traditional WCDs can be uncomfortable, require frequent maintenance, and cannot be used when showering, resulting in poor compliance and avoidable SCA deaths.
View Article and Find Full Text PDFNo beneficial use of the wearable cardioverter defibrillator among patients suffering from inherited and congenital heart disease: data from a European multicenter registry.
Front Cardiovasc Med
July 2024
Department of Cellular and Translational Physiology and Institute für Forschung und Lehre (IFL), Institute of Physiology, Molecular and Experimental Cardiology, Ruhr-University Bochum, Bochum, Germany.
Article Synopsis
- The study looked at how helpful a wearable device, called a cardioverter defibrillator, is for patients with inherited and congenital heart diseases.
- Only 18 patients were observed, showing that half were men, and they had various heart issues.
- The results suggest that using this device doesn’t really help most patients with these specific heart problems, as only a few showed any benefits.
First human safety and effectiveness study of defibrillation with a novel patch wearable cardioverter-defibrillator.
Europace
July 2024
Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic.
Aims: Wearable cardioverter-defibrillators (WCDs) are indicated in patients at risk of sudden cardiac arrest who are not immediate candidates for implantable defibrillator therapy. Limitations of existing WCDs include poor compliance and high false alarm rates. The Jewel is a novel patch-WCD (P-WCD) that addresses these limitations with an adhesive-based design for near-continuous wear and a machine learning algorithm designed to minimize inappropriate detections.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!